Indian stocks: Visit www.stage2stocks.com →

BioAge Labs, Inc.

Stage 4 · Declining · week 7

As of Oct 22, 2026, BioAge Labs is in Stage 4, the downtrend phase, now in week 7 (since Sep 3, 2026). It closed at $5.53, 78.0% below its 52-week high and below its 200-day average, which is falling.

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. More about the company

$5.53
+0.36% today
$254M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BIOA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2024-09-26 → 2026-10-22
S? 42w
S1 10w
S2 29w
S3 10w
2024-09-262026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S1 10w → S2 29w → S3 10w → S2 7w → S3 3w → S4 7w current
Total tracked: 108 weeks across 7 stage runs.

BIOA among Drug Manufacturers - Specialty & Generic29th of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…29BIOAStage 4 · wk 758−29.9%
vs 52W High
-78.0%
$4.84 lo$25.10 hi
78.0% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 7
1w13w26w
Week 7, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-65.8%
200 DMA: $16.17 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.66x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-29.9%
3M
-74.6%
6M
-67.9%
YTD
-56.9%
1Y
+4.3%
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-22S4
Wk 7 · Vol 0.66x
2026-10-21S4
Wk 7 · Vol 0.66x
2026-10-20S4
Wk 7 · Vol 1.66x
2026-10-19S4
Wk 7 · Vol 1.73x
2026-10-16S4
Wk 7 · Vol 1.21x
2026-10-15S4
Wk 6 · Vol 1.12x
2026-10-14S4
Wk 6 · Vol 0.81x
2026-10-13S4
Wk 6 · Vol 0.78x
2026-10-12S4
Wk 6 · Vol 0.48x
2026-10-09S4
Wk 6 · Vol 0.66x
2026-10-08S4
Wk 5 · Vol 0.90x
2026-10-07S4
Wk 5 · Vol 0.79x
Moving averages & range
50 DMA
$7.97
200 DMA
$16.17
52W High
$25.10
52W Low
$4.84
5D Low
$4.84
Resistance levels (recent highs)
20d High
$7.18
60d High
$24.85
120d High
$25.10
250d High
$25.10
Next resistance
+29.8%
to 20d High
ROE
-28.2%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.7

BioAge Labs: quick answers

What stage is BioAge Labs in?

As of Oct 22, 2026, BioAge Labs (BIOA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 3, 2026 and is in week 7. What the four stages mean

Is BioAge Labs in an uptrend?

No. BioAge Labs is in a Stage 4 downtrend. It trades 65.8% below its 200-day average, which is falling.

How far is BioAge Labs from its 52-week high?

BioAge Labs closed at $5.53 on Oct 22, 2026, 78.0% below its 52-week high of $25.10. Its 52-week low is $4.84.

How has BioAge Labs performed over the past year?

As of Oct 22, 2026, BioAge Labs is up 4.3% over the past year and down 56.9% so far in 2026.

Which sector and industry is BioAge Labs in?

BioAge Labs is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.